Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

645
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Angina IV: Management01:26

Angina IV: Management

22
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
22
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Sex-Related Differences in On-Treatment Platelet Reactivity in Patients with Acute Coronary Syndrome.

Biomedicines·2025
Same author

Elderly patients are hyperresponsive to potent P2Y12 inhibitors.

Research and practice in thrombosis and haemostasis·2025
Same author

Platelet reactivity is associated with pump thrombosis in patients with left ventricular assist devices.

Research and practice in thrombosis and haemostasis·2024
Same author

Isolated pulmonary valve endocarditis.

Wiener klinische Wochenschrift·2024
Same author

Omission of Antiplatelet Therapy in Patients With HeartMate 3 Left Ventricular Assist Devices: A Systematic Review and Meta-Analysis.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2024
Same author

Anticoagulation in atrial fibrillation and end-stage kidney disease on hemodialysis: a meta-analysis of randomized trials comparing direct oral anticoagulants with vitamin K antagonists.

Research and practice in thrombosis and haemostasis·2024

Video Experimental Relacionado

Updated: Sep 10, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.2K

Tratamiento antiplaquetario con clopidogrel versus aspirina en la enfermedad cardiovascular aterosclerótica: una

Maximilian Tscharre1, David Mutschlechner2, Kurt Huber3

  • 1Department of Internal Medicine, Cardiology and Nephrology, Landesklinikum Wiener Neustadt, Austria; Institute of Vascular Medicine and Cardiac Electrophysiology, Karl Landsteiner Society, St. Pölten, Austria; Department of Medicine, Faculty of Medicine and Dentistry, Danube Private University, Krems, Austria.

Atherosclerosis
|August 22, 2025
PubMed
Resumen

La terapia antiplaquetaria única con clopidogrel reduce significativamente los eventos adversos cardiovasculares mayores (MACE) en comparación con la aspirina en la enfermedad cardiovascular aterosclerótica. Este beneficio se obtiene sin un aumento en el riesgo de hemorragias.

Palabras clave:
Las aspirinasEnfermedad cardiovascular ateroscleróticaEl clopidogrelMonoterapiaPrevención secundariaTratamiento antiplaquetario único

Más Videos Relacionados

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.0K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K

Videos de Experimentos Relacionados

Last Updated: Sep 10, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.2K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.0K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K

Área de la Ciencia:

  • Cardiología
  • Farmacología
  • Ensayos clínicos

Sus antecedentes:

  • El tratamiento de la enfermedad cardiovascular aterosclerótica (ASCVD, por sus siglas en inglés) a menudo implica terapia antiplaquetaria.
  • La eficacia y la seguridad comparativas del clopidogrel frente a la aspirina para la terapia antiplaquetaria única (SAPT) en la EASC siguen siendo objeto de investigación.

Objetivo del estudio:

  • Evaluar sistemáticamente si el clopidogrel como SAPT ofrece una eficacia isquémica superior a la de la aspirina.
  • Evaluar si el clopidogrel tiene un perfil de hemorragia más favorable que la aspirina en pacientes con VSAC.

Principales métodos:

  • Se realizó una búsqueda sistemática de la literatura en las bases de datos de Medline, Web of Science y Embase hasta el 21 de abril de 2024.
  • El análisis incluyó solo ensayos controlados aleatorios, centrados en los eventos adversos cardiovasculares mayores (EACM) como punto final primario.
  • Las proporciones de probabilidades (OR) se calcularon utilizando un modelo de efectos aleatorios para tener en cuenta la heterogeneidad potencial.

Principales resultados:

  • Se analizaron seis ensayos aleatorizados en los que participaron 33.508 pacientes.
  • El clopidogrel redujo significativamente la MACE (OR 0,85) en comparación con la aspirina, impulsado por reducciones en el infarto de miocardio y accidente cerebrovascular no fatales.
  • No se observó un aumento significativo de los eventos hemorrágicos totales o severos con clopidogrel.

Conclusiones:

  • La terapia antiplaquetaria única con clopidogrel demuestra una eficacia isquémica superior a la de la aspirina en pacientes con enfermedad cardiovascular aterosclerótica.
  • El clopidogrel ofrece un perfil de riesgo de hemorragia comparable al de la aspirina, lo que lo convierte en una opción potencialmente preferida para el tratamiento de la EACV.